Latest news with #cancerDetection
Yahoo
09-07-2025
- Business
- Yahoo
Grail (GRAL) PT Hiked to $38 at Morgan Stanley amid ‘Equal Weight' Stance
Grail, Inc. (NASDAQ:GRAL) is one of the 15 successful spin-off companies. On June 25, Morgan Stanley reiterated an 'Equal Weight' on the stock. However, the investment bank raised its price target to $38 from $20. The adjustment is in response to the stock rallying by more than 150% year to date. A hand holding cancer cells with a magnifying glass, highlighting the company's target of curing diseases. Morgan Stanley remains optimistic, given the long-term potential of the company's Galleri multi-cancer early detection test. The test is tailored to detect multiple types of cancer through a single blood draw before symptoms appear. Grail has positioned the Galleri test as a potential breakthrough in cancer screening. Nevertheless, Morgan Stanley insists the company faces inherent risks tied to the regulatory reimbursement pathway perspective. The investment firm has highlighted challenges in the development of cancer tests, including gaining widespread adoption and securing insurance coverage. Grail, Inc. (NASDAQ:GRAL) is a healthcare company focused on developing blood tests for early cancer detection. Its primary goal is to enhance cancer detection at earlier stages when it may be more treatable and potentially curable. The company was formed following its spin-off from Illumina in 2024. While we acknowledge the potential of GRAL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
08-07-2025
- Business
- Yahoo
iCAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote 'FOR' Proposed Acquisition by RadNet, Inc.
NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ('iCAD' or the 'Company'), a global leader in clinically proven AI-powered cancer detection solutions, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ('ISS') and Glass, Lewis & Co. ('Glass Lewis') have each recommended that stockholders vote 'FOR' the previously announced acquisition of the Company by RadNet, Inc. ('RadNet') at the Company's upcoming Special Meeting of Stockholders scheduled for July 14, 2025, at 9:00 a.m. ET to be held virtually at As previously announced, iCAD entered into a definitive merger agreement under which RadNet will acquire iCAD in an all-stock transaction. The acquisition is structured to accelerate the deployment of iCAD's ProFound AI® breast health solutions across RadNet's DeepHealth portfolio, expanding access to early breast cancer detection. ISS and Glass Lewis each reviewed the transaction and concluded that it is in the best interests of iCAD stockholders. Both firms cited the Board's reasonable review of alternatives, the implied premium and the opportunity for iCAD stockholders to participate in the potential upside of the combined entity in their 'FOR' recommendations1. iCAD's Board of Directors also unanimously recommends that stockholders vote 'FOR' the merger, and all related matters to be voted upon at the Special Meeting. Stockholders of record as of May 16, 2025, are eligible to vote and may do as at any time prior to the Special Meeting. Voting instructions, including how to submit a proxy online, by phone, or mail, are included in the Proxy Statement. If you have any questions about the Special Meeting or require assistance voting your shares, please contact iCAD's proxy solicitor, Campaign Management, at 844-394-4517 or via email at info@ 1Permission to cite ISS and Glass Lewis was neither sought nor obtained. ABOUT iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection and density assessment. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit No Offer or Solicitation This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. It does not constitute a prospectus or prospectus equivalent document. No offering or sale of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the 'Securities Act'), and otherwise in accordance with applicable law. Important Information about the Proposed Transaction and Where to Find It In connection with the proposed transaction between RadNet and iCAD, on May 6, 2025, RadNet filed with the Securities and Exchange Commission ('SEC') a registration statement on Form S-4, as amended on May 19, 2025, that constitutes a prospectus of RadNet and also includes a definitive proxy statement of iCAD. The registration statement was declared effective by the SEC on May 21, 2025, and iCAD commenced mailing the proxy statement/prospectus to its stockholders on or about May 21, 2025. The proxy statement/prospectus filed with the SEC related to the proposed merger contains important information about RadNet, iCAD, and the proposed transaction, and related matters. RadNet and iCAD may also file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for the proxy statement/prospectus or any other document which RadNet or iCAD may file with the SEC. Investors are urged to carefully read the proxy statement/prospectus and other documents filed or to be filed with the SEC (or incorporated by reference into the proxy statement/prospectus), as well as any amendments or supplements to these documents, in connection with the proposed transaction, when available, because they contain, or will contain, as applicable, important information about the proposed transaction and related matters. Investors are able to obtain free copies of the registration statement on Form S-4 and the proxy statement/prospectus, and other documents filed by RadNet or iCAD with the SEC through the website maintained by the SEC at Copies of the documents filed with the SEC by RadNet can be obtained by contacting RadNet's Investor Relations by telephone at (310) 445-2800 or by mail at 1510 Cotner Avenue, Los Angeles, California 90025. In addition, investors are able to obtain free copies of the documents filed with the SEC on RadNet's website at (which website is not incorporated herein by reference). Copies of the documents filed with the SEC by iCAD can be obtained by contacting iCAD's proxy solicitor, Campaign Management, at 844-394-4517 or via email at info@ or Investor Relations by telephone at (603) 882-5200 or by mail at 2 Townsend West, Suite 6, Nashua, New Hampshire 03063. In addition, investors are able to obtain free copies of the documents filed with the SEC on iCAD's website at (which website is not incorporated herein by reference). Participants in the Solicitation RadNet, iCAD and their respective directors and executive officers may be considered participants in the solicitation of proxies from iCAD's stockholders in connection with the proposed transaction. Information about the directors and executive officers of RadNet is set forth in its proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on April 28, 2025. Information about the directors and executive officers of iCAD is set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2025. To the extent holdings of RadNet's or iCAD's securities by its directors or executive officers have changed since the amounts set forth in such filings, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, and other information regarding the potential participants in the proxy solicitations, which may be different than those of RadNet's stockholders and iCAD's stockholders generally, is, or will be, contained, as applicable, in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction. You may obtain these documents (when they become available) free of charge through the website maintained by the SEC at and from the investor relations departments at RadNet or iCAD or from RadNet's website or iCAD's website, in each case, as described above. Forward-Looking Statements This communication contains certain 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'outlook,' 'plan,' 'potential,' 'possible,' 'predict,' 'project,' 'seek,' 'should,' 'target,' 'will' or 'would,' the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the anticipated benefits of the proposed transaction, the impact of the proposed transaction on RadNet's and iCAD's business and future financial and operating results and prospects, the amount and timing of synergies from the proposed transaction and the closing date for the proposed transaction are based on the current estimates, assumptions and projections of RadNet and iCAD, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet's and iCAD's control. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of RadNet's and iCAD's business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet's and iCAD's control. RadNet's, iCAD's and RadNet's actual results and financial condition following the proposed transaction may differ materially from those indicated in the forward-looking statements as a result of various factors. None of RadNet, iCAD or any of their respective directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet or iCAD. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet's and iCAD's businesses, the proposed transaction and the ability to successfully complete the proposed transaction and realize its expected benefits. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the termination of or occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement or the inability to complete the proposed transaction on the anticipated terms and timetable, (2) the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders of iCAD or to satisfy any other condition to closing in a timely manner or at all, or the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated, (3) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, the ability of RadNet or iCAD to maintain relationships with its customers, patients, payers, physicians, and providers and retain its management and key employees, (4) the ability of RadNet following the proposed transaction to achieve the synergies contemplated by the proposed transaction or such synergies taking longer to realize than expected, (5) costs related to the proposed transaction, (6) the ability of RadNet following the proposed transaction to execute successfully its strategic plans, (7) the ability of RadNet following the proposed transaction to promptly and effectively integrate iCAD into its business, (8) the risk of litigation related to the proposed transaction, (9) the diversion of management's time and attention from ordinary course business operations to completion of the proposed transaction and integration matters, (10) the risk of legislative, regulatory, economic, competitive, and technological changes, (11) risks relating to the value of RadNet's securities to be issued in the proposed merger, (12) the effect of the announcement, pendency or completion of the proposed transactions on the market price of the common stock of each of RadNet and iCAD, and (13) risks specific to the Company, including: the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet's and iCAD's respective filings with the SEC, including the risk factors discussed in RadNet's and iCAD's most recent Annual Reports on Form 10-K, as updated by their respective Quarterly Reports on Form 10-Q and future filings with the SEC, as well as the proxy statement/prospectus filed with the SEC in connection with the proposed transaction. Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, neither RadNet nor iCAD undertakes any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement. CONTACT:Media Inquiries:pr@ Investor Inquiries:John Nesbett/Rosalyn ChristianIMS Investor Relationsicad@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-07-2025
- Health
- Yahoo
New blood test detects cancers 3 years before typical diagnosis, study hints
When you buy through links on our articles, Future and its syndication partners may earn a commission. Blood plasma can harbor DNA changes that could flag cancer years before existing diagnostic tests, an early study hints. The recent study, published May 22 in the journal Cancer Discovery, found traces of free-floating DNA from dead precancerous or cancerous cells in plasma that had been donated three years before a diagnosis. "It's an important step toward preclinical cancer detection, which could potentially revolutionize cancer screening," said Catherine Alix-Panabières, a cancer researcher at the University of Montpellier in France who was not involved with the work. "Earlier detection typically correlates with better outcomes across many cancer types due to earlier intervention," she told Live Science in an email. The prognosis for cancer patients generally grows worse the later their disease is caught, especially once it has grown and spread to other tissues. Yet the gene changes, or mutations, that give rise to tumors tend to appear decades beforehand. Consultant oncologist Dr. Yuxuan Wang at Johns Hopkins University and her colleagues wanted to see if they could detect tumor DNA in plasma long before cancer manifests. They examined plasma — the liquid that blood cells are suspended within — that was collected from patients roughly 40 years ago for an unrelated study. They focused on 26 participants who had developed cancer within six months of donating blood, as well as 26 controls who did not develop cancer for at least 17 years post-donation. Related: Simple blood tests could be the future of cancer diagnosis Wang's group found between one and three common cancerous mutations in seven of the plasma samples, all of which were taken from participants that developed cancer within four months of donating blood. Six of these patients had also donated blood between 3.1 and 3.5 years beforehand, so Wang's team turned back the clock further and assessed those earlier samples for the same mutations. Two of the early samples contained the same DNA errors, confirming that these warning signs were detectable years before the tumors appeared, at least in some people. Since they found only a few common mutations in two of the six plasma samples taken three years before diagnosis, they then sequenced the plasma DNA to find additional mutations that were unique to each patient. Using the genomes of their white blood cells — a type of immune cell — as a reference, they found between four and 90 unique mutations in the plasma DNA from three patients. All told, they found hints of cancer in three of the five early samples they examined. The patients in this study had a variety of cancers, including breast, colon, liver, lung, pancreas, and rectal cancer. However, it's not clear if the testing method works equally well for all tumor types. "Some organs will shed tumor DNA more than others," Wang told Live Science, noting that the blood-brain barrier, a protective membrane, may prevent brain cancer DNA crossing out of the organ and into the bloodstream. In addition, the new research didn't find any cancer DNA in 18 of the 26 participants who developed tumors in the months after their samples were collected. That's not ideal for a clinical test, Wang said. But she suggested that detection could potentially improve if doctors took larger volumes of plasma from each patient. Since the test could potentially detect cancer years before symptoms first appear, it could one day be useful for screening patients preemptively. However, further experiments are needed to ensure this diagnostic doesn't lead to false positive results, which could unnecessarily alarm patients and possibly lead to unnecessary treatments or invasive diagnostic procedures, like biopsies. "Ethically, implementing such tests in routine screening would require clear guidelines on how to handle incidental findings," Alix-Panabières said. And because the study only included plasma samples from 52 people, larger investigations involving hundreds or thousands of participants would be needed to validate the test before doctors could use it with confidence. "Realistically, widespread clinical adoption may take another 5–10 years," Alix-Panabières predicted. RELATED STORIES —Detecting cancer in minutes possible with just a drop of dried blood and new test, study hints —New blood test detects ovarian cancer years before conventional methods —Simple blood test could reveal likelihood of deadly skin cancer returning, study suggests Finding personalized mutations requires sequencing the patient's DNA, which can cost several hundred or thousands of dollars, Wang said. So even if such a test can be validated in larger trials, it's "probably not going to be something we can provide for everyone who we want to screen," and the test may need to be reserved for at-risk groups whose families have known histories of cancer, for instance. The recent study consisted mostly of Black and white men and women between the ages 45 to 64 from four U.S. states. Future investigations could explore the efficiency of the test in people from other, genetically diverse backgrounds. This article is for informational purposes only and is not meant to offer medical advice.
Yahoo
05-07-2025
- Business
- Yahoo
Lunit partners with Microsoft to develop AI cancer diagnostic tools
South Korean AI company Lunit is collaborating with Microsoft to help bring its AI-powered diagnostics for cancer detection into clinical practice. According to Lunit, the partnership aligns with its vision to create AI tools that fit smoothly into everyday clinical care. The collaboration will involve Lunit and Microsoft's development of a tool for customising AI models that will be embedded into Microsoft's Azure cloud platform, thereby allowing Lunit users to customise their AI models using site-specific clinical data. Lunit adds that the approach will mitigate cross-site model performance variability, which it views as a key hurdle in the deployment of AI diagnostics in real-world clinical settings. The developer also plans to use Microsoft's agentic AI frameworks, which are designed to support intelligent task automation, to develop workflow automation tools. According to Lunit, these solutions will simplify clinical decision-making and improve operational efficiency for its AI cancer diagnostic tools. Lunit's AI tools include the SCOPE HER2 algorithm for human epidermal growth factor receptor 2 (HER2) biomarker evaluation in metastatic colorectal cancer (mCRC) patients undergoing HER2-targeted therapy, and INSIGHT DBT for identifying breast cancer in mammogram images. Lunit CEO Brandon Suh commented: 'Our collaboration with Microsoft enables us to bring our AI to more providers through trusted platforms like Microsoft Azure, helping us expand access in the US and beyond.' According to GlobalData analysis, the use of AI across healthcare is rapidly advancing, with the market projected to reach a valuation of around $19bn by 2027. Radiology has emerged as one of the most common areas in which AI is being applied – chiefly as a means to drive efficiencies and glean insights that humans evaluating radiologic images could miss. Naveen Valluri, general manager of health and life sciences data and AI at Microsoft, commented: 'With Microsoft Azure, we are shaping an ecosystem that supports partners like Lunit in delivering scalable AI innovations. 'By combining our infrastructure with clinical-grade AI developed in close collaboration with leaders like Lunit, we're accelerating the development of integrated solutions for radiology and beyond.' "Lunit partners with Microsoft to develop AI cancer diagnostic tools" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Forbes
01-07-2025
- Health
- Forbes
SpotitEarly Breath Test Uses AI And Dogs For Early Cancer Detection
SpotitEarly CEO Shlomi Madar with his late grandfather The next breakthrough in cancer screening is emerging from the convergence of artificial intelligence and canine biology. That's the thesis behind SpotitEarly, a startup that recently launched in the U.S. with $20 million in funding. The company's hybrid platform combines trained dogs with artificial intelligence to deliver an early cancer detection breath test with 94% accuracy, targeting breast, colorectal, prostate and lung cancers. More than 70% of cancers are still diagnosed after symptoms appear—when survival rates plummet. In the U.S., the average cancer screening rate among eligible adults remains below 60%, despite massive investments in awareness and infrastructure. And while diagnostics innovation has exploded, access has not. Many tools are either cost-prohibitive, unproven, or designed for a healthcare experience that caters to the few. In an era where longevity startups cater to the 1% with concierge diagnostics and $2,500 full-body scans, SpotitEarly is flipping the script. Its goal: to bring cutting-edge early detection to the millions who never make it to screening in time—not just those with the means to optimize wellness. SpotitEarly are beagles trained to detect cancer. SpotitEarly is poised to shake up a diagnostics market plagued by high costs, access disparities and screening inertia—with a scientifically validated, double-blind clinical trial to back it. 'After years in cancer care, I've seen firsthand how late diagnoses steal lives. SpotitEarly is changing that. By combining AI with a dog's powerful sense of smell, they're making early detection for multiple cancers faster, more accessible, and more affordable than anything I've seen in the field. This is a true breakthrough—and a chance to save lives at scale,' said Dr. David Sidransky, Professor of Oncology at Johns Hopkins Medical School and current advisory board member at SpotitEarly. Revolutionizing Non-Invasive Cancer Screening With Dogs And AI SpotitEarly enables users to collect a breath sample at home and mail it to the company's lab. There, trained beagles detect cancer-linked volatile organic compounds (VOCs), while the company's LUCID platform digitizes the dogs' behavioral data and uses AI to interpret the results. The company's approach was tested in a double-blind clinical trial involving 1,400 participants in Israel, conducted in collaboration with Tel Aviv Sourasky Medical Center, Rambam Health Care Campus and Hadassah Medical Center. Neither the dog trainers, sample handlers, AI system operators, nor analysts knew whether the samples came from individuals with cancer or healthy controls. All samples were randomized, anonymized and processed independently to ensure clean, unbiased results. The study achieved 94% sensitivity and specificity across four major cancers—breast, colorectal, prostate and lung—and the results were published in Scientific Reports in November 2024. SpotitEarly Founder and CEO Shlomi Madar 'This wasn't an anecdotal pilot,' said CEO Shlomi Madar, PhD. 'We conducted a rigorous, double-blind, multi-site trial with academic partners to validate our platform scientifically. That level of proof is what makes us different from the many promising but unproven efforts in this space.' In the end, SpotitEarly isn't just about better diagnostics—it's about giving families more time together. Why Can Dogs Detect Cancer Better Than Machines Alone? Dogs have up to 300 million olfactory receptors—tens of thousands more than humans. They can detect scent at concentrations as low as parts per trillion, which is why they've long been used to find explosives, contraband and even viral infections. Decades of studies have shown that dogs can identify the presence of cancer by smell, often before clinical symptoms appear. SpotitEarly is among the first to pair that natural ability with digital infrastructure and machine learning. Each canine's sniffing behavior is tracked by sensors and algorithms that quantify subtle physiological cues, such as sniff duration, hesitation or posture. These data streams power the company's proprietary LUCID platform, which converts biological inputs into a structured diagnostic signal. SpotitEarly estimates that one canine-AI lab can process over one million samples annually, with turnaround times of just a few days. A Mission Rooted In Personal Loss And Innovation What began as a search for better diagnostics became his introduction to a company grounded in biology, technology and accessibility. For Shlomi Madar, PhD, the pursuit of earlier cancer detection is deeply personal. He lost his grandfather to cancer, a diagnosis that came only after symptoms had already advanced. By then, treatment options were limited, and time was short. SpotitEarly CEO Dr. Shlomi Madar with his late grandparents Losing him at a relatively young age was devastating for Shlomi's family – but ultimately sparked his passion for cancer research. Learning of their shared vision to leverage their unique skills in a groundbreaking venture for the greater good, Shlomi joined the 4 founders of SpotitEarly, whose team discovered the untapped potential of canine scent detection—and the power of pairing it with machine learning to create a scalable, noninvasive diagnostic platform. Their mission was to make early detection accessible to everyone, not just the fortunate few. SpotitEarly plans to make its at-home cancer detection test available directly to customers through a physician network starting in 2026. A single-cancer test will cost about $250, while a comprehensive panel for all four cancers will cost around $500. No clinic visit or specialist referral is required. The company will continue to partner with health systems and research institutions to enhance accessibility and validate its technology. If a breath test detects potential cancer biomarkers, users will receive clear, secure results along with guidance on what to do next. Results can be easily shared with a physician, who can then recommend diagnostic follow-ups and a personalized care plan. The product is not yet covered by insurance, though the company is in active conversations with payers. Even without reimbursement, SpotitEarly's pricing undercuts most early detection tools. It's positioned as a low-barrier, high-sensitivity option, particularly attractive for younger or underserved patients who may not qualify for traditional screenings. The at-home format eliminates friction. Users receive a kit, provide a breath sample in minutes and return it by mail. Results will be delivered within days. The early detection market is growing rapidly, with players like Grail's Galleri offering liquid biopsies and startups like Prenuvo providing full-body MRI scans. But these approaches are often expensive, inaccessible, or both. Prenuvo's scans cost between $1,000 and $2,500 (and up to $4,000 in premium markets), and they are typically not covered by insurance. Appointments require travel to specialized imaging centers and can take over an hour to complete. While comprehensive, the model primarily caters to the 1%—those investing in concierge diagnostics and longevity-focused wellness, rather than scalable population health tools. SpotitEarly offers a more targeted and affordable solution. Its test is: It also avoids one of the most cited concerns about full-body scans: overdiagnosis. These scans can detect benign anomalies that trigger unnecessary follow-ups and patient anxiety. SpotitEarly's method focuses on cancers with the most robust breath-based biomarkers and the clearest public health benefits when detected early. As Madar noted in a recent interview, 'Prenuvo costs patients around $2,500. Most Americans can't cover a $1,000 emergency expense.' SpotitEarly is betting that affordability, not abundance, is the future of early detection. The company has raised $20.3 million to date from backers including Hanaco Ventures, Jeff Swartz (former CEO of Timberland), and Avishai Abrahami (cofounder of Wix). Funds are being used to scale U.S. operations, conduct further validation studies and prepare for commercial rollout in 2026. SpotitEarly's use of dogs and data may seem unconventional—even a little unexpected—but the implications are anything but light. The company is tackling one of the most persistent failures in healthcare: the gap between innovation and access. Despite decades of investment in awareness and infrastructure, over 70% of cancers are still diagnosed after symptoms appear—when outcomes are far worse. In the U.S., fewer than 60% of eligible adults get the screenings they need. Meanwhile, diagnostics innovation has surged, but too often it's priced for exclusivity, not equity. Where companies like Prenuvo serve the 1% with concierge scans and longevity optimization, SpotitEarly is building for the other 99%—those for whom early detection is not just a wellness upgrade, but a matter of survival. Its breath-based platform offers a rare blend of scientific rigor, scalability, and affordability. If the model holds, SpotitEarly won't just catch cancer earlier—it could reshape how health systems approach prevention, precision, and who innovation is actually designed for. In a healthcare landscape where flashy technology often outpaces clinical validation, SpotitEarly flips the script—starting with biology, validating it with science, and scaling it through tech. SpotitEarly's use of dogs and data may seem unconventional—even a little unexpected—but the implications are anything but light. The company is tackling one of the most persistent failures in healthcare: the gap between innovation and access. Despite decades of investment in awareness and infrastructure, over 70% of cancers are still diagnosed after symptoms appear, when outcomes are far worse. In the U.S., fewer than 60% of eligible adults get the screenings they need. Meanwhile, diagnostics innovation has surged, but too often it's priced for exclusivity, not equity. Where companies like Prenuvo serve the 1% with concierge scans and longevity optimization, SpotitEarly is building for the other 99%—those for whom early detection is not just a wellness upgrade, but a matter of survival. Its breath-based platform offers a rare blend of scientific rigor, scalability, and affordability. Read more in Forbes about how AI Is Catching What Mammograms Miss and a Blood Test Could Detect Cancer Up To Seven Years Earlier
